843653-25-8Relevant academic research and scientific papers
Advances toward new antidepressants with dual serotonin transporter and 5-HT1A receptor affinity within a class of 3-aminochroman derivatives. Part 2
Hatzenbuhler, Nicole T.,Baudy, Reinhardt,Evrard, Deborah A.,Failli, Amedeo,Harrison, Boyd L.,Lenicek, Steven,Mewshaw, Richard E.,Saab, Annmarie,Shah, Uresh,Sze, Jean,Zhang, Minsheng,Zhou, Dahui,Chlenov, Michael,Kagan, Michael,Golembieski, Jeannette,Hornby, Geoffrey,Lai, Margaret,Smith, Deborah L.,Sullivan, Kelly M.,Schechter, Lee E.,Andree, Terrance H.
experimental part, p. 6980 - 7004 (2009/11/30)
Novel compounds combining a 5-HT1A moiety (3-aminochroman scaffold) and a 5-HT transporter (indole analogues) linked through a common basic nitrogen via an alkyl chain attached at the 1- or 3-position of the indole were evaluated for dual affin
Synthesis and biological evaluation of novel compounds within a class of 3-aminochroman derivatives with dual 5-HT1A receptor and serotonin transporter affinity
Hatzenbuhler, Nicole T.,Evrard, Deborah A.,Harrison, Boyd L.,Huryn, Donna,Inghrim, Jennifer,Kraml, Christina,Mattes, James F.,Mewshaw, Richard E.,Zhou, Dahui,Hornby, Geoffrey,Lin, Qian,Smith, Deborah L.,Sullivan, Kelly M.,Schlechter, Lee E.,Beyer, Chad E.,Andree, Terrance H.
, p. 4785 - 4789 (2007/10/03)
Compounds containing a 5-carbamoyl-8-fluoro-3-amino-3,4-dihydro-2H-1- benzopyran and a 3-alkylindole moiety linked through a common basic nitrogen were prepared and evaluated for 5-HT1A affinity, serotonin rat transporter affinity, and functional antagonist activity in vitro. 26a was found to be the most potent and selective compound in this series and was shown to possess neurochemical activity in vivo by producing acute and rapid increases in 5-HT in the rat frontal cortex.
3-AMINO CHOMAN AND 2-AMINO TETRALIN DERIVATIVES
-
Page/Page column 97, (2010/02/10)
3-Amino chroman and 2-amino tetralin derivatives and compositions containing such compounds are disclosed. Methods of using the 3-amino chroman and 2-amino tetralin compounds and compositions containing such compounds in the treatment of serotonin disorders, such as depression and anxiety, are also disclosed.
